171 related articles for article (PubMed ID: 28162021)
1. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
[TBL] [Abstract][Full Text] [Related]
2. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
Rappaport JA; Waldman SA
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
[No Abstract] [Full Text] [Related]
3. GUCY2C ligand replacement to prevent colorectal cancer.
Blomain ES; Pattison AM; Waldman SA
Cancer Biol Ther; 2016 Jul; 17(7):713-8. PubMed ID: 27104761
[TBL] [Abstract][Full Text] [Related]
4. Guanylyl cyclase C signaling axis and colon cancer prevention.
Pattison AM; Merlino DJ; Blomain ES; Waldman SA
World J Gastroenterol; 2016 Sep; 22(36):8070-7. PubMed ID: 27688649
[TBL] [Abstract][Full Text] [Related]
5. GUCY2C-targeted cancer immunotherapy: past, present and future.
Snook AE; Magee MS; Waldman SA
Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
[TBL] [Abstract][Full Text] [Related]
6. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
Lin JE; Colon-Gonzalez F; Blomain E; Kim GW; Aing A; Stoecker B; Rock J; Snook AE; Zhan T; Hyslop TM; Tomczak M; Blumberg RS; Waldman SA
Cancer Res; 2016 Jan; 76(2):339-46. PubMed ID: 26773096
[TBL] [Abstract][Full Text] [Related]
7. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention.
Yarla NS; Gali H; Pathuri G; Smriti S; Farooqui M; Panneerselvam J; Kumar G; Madka V; Rao CV
Semin Cancer Biol; 2019 Jun; 56():168-174. PubMed ID: 30189250
[TBL] [Abstract][Full Text] [Related]
8. GUCY2C molecular staging personalizes colorectal cancer patient management.
Gong JP; Schulz S; Hyslop T; Waldman SA
Biomark Med; 2012 Jun; 6(3):339-48. PubMed ID: 22731908
[TBL] [Abstract][Full Text] [Related]
9. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
[TBL] [Abstract][Full Text] [Related]
10. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.
Entezari AA; Snook AE; Waldman SA
Expert Opin Ther Targets; 2021 May; 25(5):335-346. PubMed ID: 34056991
[TBL] [Abstract][Full Text] [Related]
11. GUCY2C: at the intersection of obesity and cancer.
Kim GW; Lin JE; Waldman SA
Trends Endocrinol Metab; 2013 Apr; 24(4):165-73. PubMed ID: 23375388
[TBL] [Abstract][Full Text] [Related]
12. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.
Wilson C; Lin JE; Li P; Snook AE; Gong J; Sato T; Liu C; Girondo MA; Rui H; Hyslop T; Waldman SA
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2328-37. PubMed ID: 25304930
[TBL] [Abstract][Full Text] [Related]
13. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.
Witek M; Blomain ES; Magee MS; Xiang B; Waldman SA; Snook AE
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1188-95. PubMed ID: 24661671
[TBL] [Abstract][Full Text] [Related]
14. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.
Marszalowicz GP; Snook AE; Magee MS; Merlino D; Berman-Booty LD; Waldman SA
Oncotarget; 2014 Oct; 5(19):9460-71. PubMed ID: 25294806
[TBL] [Abstract][Full Text] [Related]
15. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
Waldman SA; Hyslop T; Schulz S; Barkun A; Nielsen K; Haaf J; Bonaccorso C; Li Y; Weinberg DS
JAMA; 2009 Feb; 301(7):745-52. PubMed ID: 19224751
[TBL] [Abstract][Full Text] [Related]
16. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
Li P; Wuthrick E; Rappaport JA; Kraft C; Lin JE; Marszalowicz G; Snook AE; Zhan T; Hyslop TM; Waldman SA
Cancer Res; 2017 Sep; 77(18):5095-5106. PubMed ID: 28916678
[TBL] [Abstract][Full Text] [Related]
17. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients.
Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
Expert Rev Mol Diagn; 2009 Nov; 9(8):777-85. PubMed ID: 19895223
[TBL] [Abstract][Full Text] [Related]
18. Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis.
Blomain ES; Lin JE; Kraft CL; Trela UT; Rock JM; Aing AS; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):557-64. PubMed ID: 23971873
[TBL] [Abstract][Full Text] [Related]
19. Molecular staging estimates occult tumor burden in colorectal cancer.
Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
Adv Clin Chem; 2010; 52():19-39. PubMed ID: 21275338
[TBL] [Abstract][Full Text] [Related]
20. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8
Xiang B; Baybutt TR; Berman-Booty L; Magee MS; Waldman SA; Alexeev VY; Snook AE
J Immunol; 2017 May; 198(9):3507-3514. PubMed ID: 28341670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]